New York, January 22, 2026, 10:02 EST — Regular session
- SXTP shares surged roughly 267% in early trading following news of a new distribution deal for its malaria-prevention drug
- Starting April 2, Runway Health will provide online consultations and home delivery for ARAKODA prescriptions
- The surge comes after a 1-for-4 reverse stock split that went into effect this week
Shares of 60 Degrees Pharmaceuticals, Inc. NASDAQ:SXTP surged over 267% Thursday, hitting $7.34 by 9:57 a.m. EST. The stock had closed Wednesday at $2.00 and traded between $5.99 and $8.62 earlier today.
The announcement came after 60 Degrees unveiled a partnership with Runway Health, a travel medicine platform. Runway will provide physician-led online consultations and, when prescribed, arrange home delivery of ARAKODA (tafenoquine), the company’s malaria-prevention pill, for travelers heading abroad.
Why it matters now: ARAKODA stands as the company’s flagship commercial product. This deal slots it directly into a consumer telehealth platform aimed at travelers ahead of their trips. Telehealth—remote medical consultations online—broadens access to prescriptions that would normally demand an in-person pre-travel clinic appointment.
Traders are also watching the capital-structure reset closely. A recent filing revealed that 60 Degrees carried out a 1-for-4 reverse stock split, effective Jan. 20, merging every four shares into one to boost the stock price per share.
Volume spiked with the price, hitting roughly 115.9 million shares by 9:37 a.m. That’s a massive jump from the three-month average of around 168,000 shares, per Investing.com data. The company’s upcoming earnings report is scheduled for March 27.
The magnitude of the move highlights just how volatile micro-cap healthcare stocks can be when a headline drops and liquidity is scarce. Early jumps often attract short-term momentum traders, fueling sharper intraday swings.
But risks remain. The release didn’t reveal the financial details of the Runway deal, and the partnership won’t kick off right away. The commercial success depends on how many travelers move from online consults to actually filling prescriptions—and whether that demand holds steady beyond the initial buzz.
Investors are keeping an eye on whether SXTP can maintain its gains following the initial surge in volume, and if the company provides further details on expected uptake. The next key date is April 2, when 60 Degrees plans to kick off its partnership with Runway Health.
Related articles: Pharmaceuticals
